Amplicon Sequencing

20 10, 2025

Technote: NGS for Biologics Development Support

webmaster2025-12-23T18:19:02+00:00

Explore the power of Next Generation Sequencing (NGS) for biologics development support with our latest whitepaper. Avance Biosciences is at the forefront of NGS testing, offering tailored solutions to support drug development initiatives and GMP manufacturing activities. Delve into real-world case studies, including CRISPR indel amplicon sequencing and insertion site studies, showcasing our expertise in assay development and validation...

Technote: NGS for Biologics Development Supportwebmaster2025-12-23T18:19:02+00:00

5 08, 2025

Case Study: Quantifying In Vivo Gene Editing in Preclinical Tissues via NGS Amplicon-Seq
Gallery

Case Study: Quantifying In Vivo Gene Editing in Preclinical Tissues via NGS Amplicon-Seq

webmaster2025-12-24T14:47:41+00:00

To support IND-enabling studies, a biotech company needed precise measurement of in vivo gene-editing efficiency in preclinical rat tissues. Avance Biosciences delivered a fully validated NGS amplicon sequencing assay capable of detecting edits as low as 1%, enabling accurate quantification across multiple tissues and guiding data-driven development decisions.

Case Study: Quantifying In Vivo Gene Editing in Preclinical Tissues via NGS Amplicon-Seqwebmaster2025-12-24T14:47:41+00:00

Avance Biosciences to Exhibit at Festival of Biologics USA 2026

FDA Increases Flexibility on CMC Requirements for Cell and Gene Therapies to Advance Innovation

How Consistent Assay Performance Reduces Batch Failures

What PERT Signals About the Future of Gene Editing Manufacturing and Regulation

What “Fit-for-Purpose” Really Means in Bioanalytical Method Development

New FDA Final Guidance on Development of Therapeutic Protein Biosimilars: Analytical Considerations for Biologics Developers